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Escherichia coli clinical isolate BD07372 of sequence type ST131 recovered from a bed sore specimen
exhibited high-level resistance to ceftazidime and cefotaxime but exhibited susceptibility to imipenem and
meropenem. The isolate harbored two -lactamase genes, the blaCTX-M-15 gene carried by an250-kbp plasmid
carrying the FIA and FIC replicons and the blaGES-5 gene carried by a class 1 integron in the chromosome.
The class A carbapenemases, which have been identified in
Gram-negative rods, involve chromosome-borne NMC-A and
SME enzymes and plasmid-borne KPC, GES, and IMI en-
zymes (15). To date, 17 variants of GES-type extended-spec-
trum -lactamases (ESBLs) have been identified (http://www
.lahey.org/Studies/), but the carbapenem hydrolytic activity has
been demonstrated only in some variants, including GES-2,
GES-4, GES-5, GES-6, and GES-14, with a substitution at the
Gly170 residue (4, 15). The blaGES-5 gene was first detected
when carried by a plasmid of Escherichia coli 365-02 from
Greece in 2004 (14). Then, detection of the blaGES-5 gene
carried by Klebsiella pneumoniae, Enterobacter cloacae, and
Pseudomonas aeruginosa has been reported in many parts of
the world (15).
E. coli clinical isolate BD07372 was recovered from a bed
sore sampled on 17 May 2007 from a 79-year-old female who
has home nursing care. She had been hospitalized for 35 days
at a secondary-care hospital in Bundang, Republic of Korea,
for the treatment of chronic renal failure, type II diabetes
mellitus, and hypertension. Multilocus sequence typing was
performed on the isolate using the seven conserved house-
keeping genes (adk, fumC, gyrB, icd, mdh, purA, and recA)
following use of the protocols available at the E. coli MLST
database website (http://mlst.ucc.ie/mlst/dbs/Ecoli), and the
isolate was identified as sequence type ST131 (allelic profile,
53-40-47-13-36-28-29).
A disk diffusion assay was performed (5), and the isolate
exhibited resistance to ampicillin, ampicillin-sulbactam, piper-
acillin-tazobactam, cefoxitin, aztreonam, ceftazidime, cefo-
taxime, cefepime, gentamicin, tobramycin, amikacin, and cip-
rofloxacin and was susceptible to imipenem, meropenem, and
trimethoprim-sulfamethoxazole. Synergy was observed be-
tween the amoxicillin-clavulanic acid (20/10-g) disk and the
ceftazidime (30-g), cefotaxime (30-g), cefepime (30-g),
and aztreonam (30-g) disks (Becton Dickinson, Spark, MD)
in double-disk synergy tests, indicating the production of ESBL
(12). Agar dilution MIC testing on Muller-Hinton agar (Difco
Laboratories, Detroit, MI) with an inoculum of 104 CFU per
spot confirmed high-level MICs of ceftazidime (256 g/ml)
and cefotaxime (256 g/ml) and low-level MICs of imipenem
(0.5 g/ml) and meropenem (0.25 g/ml) for the isolate
BD07372 (5). Clavulanic acid (Sigma, St. Louis, MO) at a fixed
concentration of 4 g/ml lowered the MICs of ceftazidime and
cefotaxime to 1 g/ml and 8 g/ml, respectively (Table 1).
Isolate BD07372 showed a positive result in the Hodge test,
which was performed using a MacConkey agar plate with an
ertapenem disk, indicating the production of a carbapenemase
(7). However, the isolate showed a negative result in the
EDTA-based double disk synergy test, which was performed
using a Mueller-Hinton agar plate with an imipenem disk and
a disk containing EDTA (750g) plus sodium mercaptoacetic
acid (2 mg), indicating that the isolate does not produce
metallo--lactamases (8). In the isoelectric focusing analysis,
three -lactamase activities with isoelectric points of 5.8, 6.1,
and 8.6, corresponding to GES-5, OXA-17, and CTX-M-15,
respectively, were detected.
PCR and sequencing experiments were performed to detect
genes encoding CTX-M-, GES-, PER-, SHV-, TEM-, and
VEB-type ESBLs as previously described (11). Isolate
BD07372 carried two -lactamase genes, the blaCTX-M-15 and
the blaGES-5 genes. The isolate transferred cefotaxime resis-
tance to the E. coli J53 azide-resistant recipient in mating
experiments (3), in which transconjugants were selected on
MacConkey agar (Difco Laboratories, Detroit, MI) plates sup-
plemented with cefotaxime (2 g/ml) and sodium azide (100
g/ml). The location of the -lactamase genes was identified by
the hybridization of I-CeuI-digested genomic DNA or S1 nu-
clease-treated linearized plasmids with probes specific for the
-lactamase genes, various replicons of plasmids, and 16S
rRNA genes as described previously (2, 9). The probe specific
for the blaCTX-M-15 gene hybridized with an 250-kbp plasmid
in both isolate BD07372 and its transconjugant, but that spe-
cific for the blaGES-5 gene did not. The 250-kbp plasmid
carried two types of replicon, FIA and FIC. Replicon sequence
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typing was performed on the plasmid as previously described
(13), and the sequence types of the replicons were identified to
be FIA (1) and FIC (1). This result is in agreement with the
previous study, which has confirmed that all the variants of
ST131 producing CTX-M-15 ESBL harbored the correspond-
ing gene on the IncF-type plasmid (6). The probe specific for
the blaGES-5 gene hybridized with an I-CeuI macrorestriction
fragment of 270 kbp carried by isolate BD07372. The probe
specific for 16S rRNA genes also hybridized with the I-CeuI
macrorestriction fragment, indicating the chromosomal loca-
tion of the blaGES-5 gene in the isolate.
To investigate genetic environments surrounding the
blaGES-5 gene, several overlapping PCR fragments obtained
from whole DNA of the E. coli isolate were sequenced with
primers corresponding to the internal region of the class 1
integron as previously described (1). Identical to the blaGES-5
gene carried by a plasmid of K. pneumoniae CHAK36, the
blaGES-5 gene was carried by a class 1 integron as a gene
cassette downstream of the attI1 recombination site. The inte-
gron had three unique gene cassettes [blaGES-5–aac(6)-IIa–
blaOXA-17/orf4] between the two conserved elements, the 5-
conserved segment (5-CS) and the 3-CS, but the 59-base
element of the third gene cassette was interrupted by a putative
transposase gene, orf4.
In summary, E. coli isolate BD07372 of ST131 harbored two
-lactamase genes, the blaCTX-M-15 gene carried by an 250-
kbp plasmid carrying the FIA and FIC replicons and the
blaGES-5 gene carried by a class 1 integron in a chromosome.
Recently, the intercontinental dissemination of an E. coli clone
of ST131 producing CTX-M-15, which was carried mostly by
IncF plasmids, has been reported (10). Emergence of an E. coli
clone of ST131 simultaneously producing CTX-M-15 and
GES-5 could be a serious threat to global health.
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TABLE 1. MICs of E. coli wild-type strain BD07372, its
transconjugant, and the recipient J53
Antimicrobial agenta
E. coli MIC (g/ml)
Wild-type
strain
BD07372b
Transconjugant
trcBD07372c
Recipient
J53
Amoxicillin-clavulanic acid 256 256 6
Piperacillin-tazobactam 256 256 1.5
Cefoxitin 128 96 12
Ceftazidime 256 16 0.25
Ceftazidime-clavulanic acid 8 0.5 0.12
Cefotaxime 256 32 0.06
Cefotaxime-clavulanic acid 1 0.06 0.06
Cefepime 256 16 0.06
Aztreonam 64 64 0.25
Imipenem 0.5 0.25 0.19
Imipenem-clavulanic acid 0.25 0.125 0.125
Meropenem 0.25 0.06 0.06
Meropenem-clavulanic acid 0.06 0.06 0.06
Ertapenem 1.5 1 0.023
Ertapenem-clavulanic acid 0.25 0.25 0.023
a Clavulanic acid was added at a fixed concentration of 4 g/ml.
b Carries blaGES-5 and blaCTX-M-15.
c Carries blaCTX-M-15.
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